Targeting of drugs to cell surface receptors.
The new approach to the treatment of cancer or to immunomodulation is drug targeting. The effort to achieve either an absolute or a relative amplification of the tumoricidal effect of anticancer drugs through increased generation or acquisition of reactive molecules at the tumor site or a reduction of the toxic molecules available to the periphery has led to a number of strategies. Among them are (1) targeting using antibodies to their fragments, hormones, carbohydrates, and growth factors; (2) retargeting using bispecific antibodies; (3) construction of chimeric genes; (4) streptavidin-biotin based immunotherapy; (5) prodrug activation strategies (ADEPT); (6) antibody-targeted superantigens; and (7) gene delivery for the purpose of gene therapy.
Ríhová
B
B
Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001672:Biocompatible Materials / Q000378:metabolism; D004337:Drug Carriers; D004705:Endocytosis; D015316:Genetic Therapy / Q000639:trends; D006133:Growth Substances / Q000378:metabolism; D006728:Hormones / Q000378:metabolism; D006801:Humans; D011108:Polymers / Q000378:metabolism; D011355:Prodrugs / Q000008:administration & dosage / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism*
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001672:Biocompatible Materials; D004337:Drug Carriers; D006133:Growth Substances; D006728:Hormones; D011108:Polymers; D011355:Prodrugs; D011956:Receptors, Cell Surface